Research ArticleFragile X Syndrome

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

See allHide authors and affiliations

Science Translational Medicine  13 Jan 2016:
Vol. 8, Issue 321, pp. 321ra5
DOI: 10.1126/scitranslmed.aab4109

Article Information

vol. 8 no. 321 321ra5

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication April 24, 2015
  • Accepted for publication November 21, 2015
  • .

Author Information

  1. Elizabeth Berry-Kravis1,*,
  2. Vincent Des Portes2,3,*,
  3. Randi Hagerman4,
  4. Sébastien Jacquemont5,6,
  5. Perrine Charles7,
  6. Jeannie Visootsak8,
  7. Marc Brinkman9,
  8. Karin Rerat10,
  9. Barbara Koumaras11,
  10. Liansheng Zhu12,
  11. Gottfried Maria Barth13,
  12. Thomas Jaecklin14,
  13. George Apostol14 and
  14. Florian von Raison14,
  1. 1Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
  2. 2National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.
  3. 3CNRS UMR 5304 (Laboratoire sur le Langage, le Cerveau et la Cognition), 69500 Bron, France.
  4. 4Medical Investigation of Neurodevelopmental Disorders Institute and Department of Pediatrics, UC Davis Medical Center, Sacramento, CA 95817, USA.
  5. 5Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.
  6. 6CHU Sainte-Justine Research Centre, Montreal, Quebec H3T 1C5, Canada.
  7. 7Département de Génétique et Cytogénétique, Unité Fonctionnelle de Génétique Médicale, Assistance Publique–Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.
  8. 8Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.
  9. 9Novartis Pharma GmbH, 90429 Nürnberg, Germany.
  10. 10Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.
  11. 11Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
  12. 12Integrated Quantitative Science, Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
  13. 13Department of Child and Adolescent Psychiatry, University Hospital of Tübingen, 72076 Tübingen, Baden-Württemberg, Germany.
  14. 14Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
  1. Corresponding author. E-mail: florian.von_raison{at}novartis.com
    • * These authors contributed equally as co-first authors.

    Altmetric

    Article usage

    Article usage: January 2016 to November 2019

    AbstractFullPdf
    Jan 20164705231418
    Feb 201644049100
    Mar 20164413064
    Apr 20162742345
    May 20162652239
    Jun 20162481455
    Jul 20161831834
    Aug 20161862430
    Sep 20161701623
    Oct 20162091930
    Nov 20161891821
    Dec 20161652137
    Jan 2017144628
    Feb 20172061816
    Mar 20171941727
    Apr 20171793235
    May 20172272239
    Jun 201713679
    Jul 20171521219
    Aug 20171581826
    Sep 20171851844
    Oct 20171361011
    Nov 20171612918
    Dec 20171311017
    Jan 20181081219
    Feb 20181651215
    Mar 201813478
    Apr 20181231518
    May 20181231212
    Jun 201898913
    Jul 2018108819
    Aug 2018671110
    Sep 2018981412
    Oct 2018822715
    Nov 20181251412
    Dec 2018119135
    Jan 20191191517
    Feb 2019852319
    Mar 2019912317
    Apr 2019551415
    May 2019914816
    Jun 20197378
    Jul 201941312
    Aug 201984516
    Sep 2019691711
    Oct 20191172919
    Nov 201949158